RESPIRATORY PANEL COMBINED III

Respiratory Panel Combined III is an advanced molecular microbiology test designed to detect multiple respiratory pathogens from a single respiratory specimen. Using highly sensitive multiplex PCR technology, the test simultaneously identifies a broad range of viruses and bacteria responsible for upper and lower respiratory tract infections, enabling rapid and accurate diagnosis.

Respiratory infections can present with symptoms such as fever, cough, sore throat, breathing difficulty, nasal congestion, chest discomfort, and pneumonia. Since different pathogens often produce similar symptoms, comprehensive respiratory panel testing helps clinicians quickly determine the exact cause of infection and initiate appropriate treatment.

Benefits of the Test

• Simultaneously detects multiple respiratory pathogens.
• Provides rapid and highly accurate results.
• Helps differentiate viral and bacterial infections.
• Supports targeted treatment decisions.
• Reduces unnecessary antibiotic usage.
• Assists in managing severe respiratory illnesses.
• Improves infection control and outbreak monitoring.
• Supports early diagnosis and timely intervention.

Why Doctors Recommend This Test

Doctors recommend this test for patients with suspected respiratory infections, severe flu-like illness, pneumonia, persistent cough, fever, breathing difficulties, unexplained respiratory symptoms, or when rapid identification of infectious agents is required. It is particularly valuable for children, elderly individuals, immunocompromised patients, hospitalized patients, and those with severe respiratory disease.

The test helps identify the causative pathogen and guides appropriate antiviral, antibacterial, or supportive treatment strategies.

Preparation Before Test

• No fasting is required.
• A respiratory specimen is collected by trained healthcare professionals.
• Nasopharyngeal swabs, throat swabs, sputum, or respiratory secretions may be used.
• Inform your doctor about any recent medications or treatments.
• Follow all instructions provided before sample collection.
• Ensure timely transportation of the specimen to the laboratory.

Normal Reporting Time

Most Respiratory Panel Combined III reports at Focus Diagnostics are available within 2–3 hours after sample processing. Complex cases or additional confirmatory testing may occasionally require additional time depending on laboratory requirements.

Who Should Take This Test?

This test may be recommended for:

• Patients with acute respiratory infections.
• Individuals with fever, cough, and breathing difficulties.
• People with suspected viral or bacterial pneumonia.
• Hospitalized patients with respiratory symptoms.
• Children and elderly individuals.
• Immunocompromised patients.
• Patients with recurrent respiratory infections.
• Individuals requiring comprehensive respiratory pathogen screening.

Detailed Information

Respiratory tract infections remain one of the most common causes of illness worldwide and can affect individuals of all ages. These infections may involve the upper respiratory tract, including the nose, throat, and sinuses, or the lower respiratory tract, including the bronchi and lungs. Clinical symptoms often overlap, making it difficult to identify the exact pathogen based solely on symptoms and physical examination.

Respiratory Panel Combined III utilizes advanced multiplex polymerase chain reaction (PCR) technology to detect genetic material from multiple respiratory pathogens simultaneously. Unlike traditional culture methods that may require several days, multiplex molecular testing provides rapid and highly sensitive identification of infectious agents.

The panel may detect a wide range of respiratory viruses and bacteria commonly associated with respiratory illness. These may include Influenza A and B viruses, Respiratory Syncytial Virus (RSV), Adenovirus, Human Metapneumovirus, Parainfluenza viruses, Rhinovirus, Enterovirus, seasonal Coronaviruses, Mycoplasma pneumoniae, Chlamydia pneumoniae, Bordetella pertussis, and other clinically relevant pathogens depending on the panel configuration.

Accurate identification of respiratory pathogens is essential for guiding treatment decisions, reducing unnecessary antibiotic use, supporting infection control measures, and preventing disease transmission. Early diagnosis can be particularly important in vulnerable populations such as infants, elderly individuals, transplant recipients, cancer patients, and those with chronic respiratory conditions.

This test is especially valuable during seasonal outbreaks, influenza epidemics, community-acquired pneumonia investigations, and hospital infection control programs. It provides clinicians with comprehensive information from a single specimen, reducing the need for multiple separate diagnostic tests.

Because respiratory symptoms can be caused by viral, bacterial, or mixed infections, multiplex respiratory panel testing significantly improves diagnostic efficiency and supports evidence-based clinical management. Results should always be interpreted alongside clinical findings, imaging studies, and other laboratory investigations.

At Focus Diagnostics, Respiratory Panel Combined III testing is performed using advanced molecular diagnostic platforms, stringent quality control procedures, and highly sensitive PCR technology to ensure accurate, reliable, and clinically meaningful results for respiratory infection diagnosis and management.